UTHR — United Therapeutics Share News
0.000.00%
Last trade - 00:00- $25.46bn
- $22.80bn
- $3.18bn
Brief: Varda Space Industries And United Therapeutics Collaborate To Advance Microgravity-Enabled Treatments For Rare Pulmonary Disease
MannKind falls after quarterly revenue miss
MannKind rises as it partners with United Therapeutics on inhaled drug for rare lung disease
United Therapeutics Q1 revenue falls 2%, misses estimates
Brief: United Therapeutics Receives FDA Regenerative Medicine Advanced Therapy Designation For Miroliverelap® For Treatment Of Acute Liver Failure
U.S. RESEARCH ROUNDUP-Doordash, Phillips 66, United Therapeutics
U.S. STOCKS ON THE MOVE-Sysco, Crowdstrike, GM
U.S. STOCKS ON THE MOVE-Agnico Eagle Mines, ProPetro, Kezar
Brief: United Therapeutics Corporation Announces Teton-1 Pivotal Study Of Tyvaso® Meets Primary Endpoint For Treatment Of Idiopathic Pulmonary Fibrosis, Exceeding Impressive Treatment Effect Seen In Teton-2
U.S. STOCKS ON THE MOVE-Insmed, United Therapeutics, CrowdStrike
United Therapeutics jumps after Tyvaso shows benefit in lung-scarring disease
United Therapeutics gains after $2 bln buyback announced
Brief: United Therapeutics Unveils $2 Bln Buyback Plan, Launches $1.5 Bln Accelerated Repurchase
Brief: United Therapeutics Corporation Announces Ralinepag Achieved 55% Reduction In Risk Of Clinical Worsening In Pivotal Pulmonary Arterial Hypertension Study, Delivering Exceptional, Highly Statistically Significant Efficacy
United Therapeutics' lung disease drug succeeds in late-stage study (updated)
United Therapeutics' blood pressure drug meets main, secondary goals in late-stage study
U.S. RESEARCH ROUNDUP-Arcellx, Costar Group, Magnite
United Therapeutics Q4 revenue growth falls short of analyst expectations
Brief: United Therapeutics Announces Positive Results From Phase 1 Study Of Miroliverelap In Patients With Acute Liver Failure